Combined positive score status in metastatic triple-negative breast cancer patients treated with sacituzumab govitecan: associated clinical characteristics and testing patterns in a Central European cohort
Key Points
Metastatic triple-negative breast cancer patients treated with sacituzumab govitecan show varied outcomes, highlighting differences in clinical characteristics.
A significant proportion of 80% of patients exhibit a positive score status, emphasizing the effectiveness of the treatment.
Assessment included a detailed review of testing patterns and patient characteristics across a Central European cohort, using systematic analysis.
Findings underscore the necessity for standardized testing and better treatment approaches in this patient population.
Like
Bookmark
Share
Like
Bookmark
Share
Cite This Study
Winsko-Szczęsnowicz et al. (Mon,) studied this question.
Der kombinierte positive Score-Status bei Patienten mit metastasiertem dreifach negativem Brustkrebs, die mit Sacituzumab Govitecan behandelt wurden: zugehörige klinische Merkmale und Testmuster in einer zentral-europäischen Kohorte | Synapse